ALK fusion‐positive NSCLC patients treated with the first‐generation ALK inhibitor crizotinib achieve an objective response rate of 60%, with a PFS of 8–10 months, and significantly prolonged OS.207, 208. Here, ALK is linked to non-small cell lung carcinoma.